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Toxoplasmosis is an important cause of congenital disease, and it is one of the
most common opportunistic infections in patients with acquired immunodeficiency
syndrome. The need for a reliable experimental model of this infection is crucial not only
for achieving a better understanding of the patho-physiology of the disease, but also for
developing better methods for evaluating new therapeutic regimens. The purpose of the
present study was to investigate the role of CD4+CD25+ T regulatory lymphocytes in
mice infected with Toxoplasma gondii. T regulatory (Treg) cells have been shown to play
an important role in our immune system in controlling the activity of other T
lymphocytes. These cells are differentiated from other T lymphocyte populations based
on the co-expression of CD4 and CD25 and expression of the Foxp3 gene. The results of
several recent studies have suggested that certain pathogens may be able to increase their
survival in the host by exploiting T reg cell activity. T regulatory cells have been shown
to control the persistence of the protozoan parasite, Leishmania major, in mice; however,
this population of cells plays only a limited role during murine infection with
Trypanosoma cruzi. In the present study we have investigated the role of Treg cells
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during murine infection with the ME49 strain of T. gondii. In vivo depletion of Treg cells
was accomplished by injecting mice with a monoclonal antibody (Mab) isolated from the
7D4 rat hybridoma cell line. This Mab is specific for the interleukin-2 receptor chain
(also known as CD25). Female Swiss Webster mice of approximately 6-7 weeks of age
were depleted of Treg cells by intraperitoneal injection of 400µg of Mab, mice were
injected once 7days prior to infection, and a second time 1 day prior to infection, with 20
tissue cysts of T. gondii. Mouse weight and tissue cyst numbers were monitored to
evaluate the impact of Treg depletion on the outcome of infection. Our results suggest
that depletion of Treg cells has little measurable impact during the acute stage of
infection with the ME49 strain of T. gondii. Further studies will be required to determine
what role, if any, these cells play in the chronic stage of murine toxoplasmosis.
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INTRODUCTION
Toxoplasma gondii
Toxoplasma gondii is an obligate intracellular protozoan parasite responsible for
the disease known as toxoplasmosis. Toxoplasma gondii infects most warm-blooded
animals including humans. The definitive host of this single-celled parasite, and the host
in which the sexual cycle of the parasite takes place, is the cat. Nicolle and Manceaux
first described the organism in 1908 after they observed the parasites in the blood, spleen,
and liver of a North African rodent, Ctenodactylus gondii (cited in Black et al., 2000).
Toxoplasma gondii infects a large proportion of the world's population but uncommonly
causes clinically significant pathology. However, certain individuals are at high risk for
severe or life-threatening disease due to this parasite. Individuals at greatest risk include
fetuses, newborns, and immunologically impaired patients. Toxoplasmosis has great
economic importance in veterinary medicine because it causes abortion in cattle and
significant neonatal loss. Toxoplasma gondii infection is widespread in humans, and in
the United States and United Kingdom, the infection rate is estimated to be 16-40% of the
population. In Central and South America and continental Europe, the infection rate is
estimated to be 50-80% (Hill and Dubey, 2002).
Most infections with T. gondii in humans are asymptomatic and infection may be
congenitally or postnatally acquired. Approximately 10-20% of those with an acute
infection will have enlarged lymph nodes in the cervical and inguinal region as well as
flu-like symptoms (fever, headache, muscle pain). The infection is generally self-limited
and the symptoms usually resolve in a few months. Toxoplasmosis has a variable
outcome depending on the interaction of many factors, including the route of infection,
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the host immune system, and host genetics. Human infections are generally acquired by
ingestion of undercooked meat or raw meat containing tissue cysts or from the ingestion
of oocysts (Hill and Dubey, 2002). Encephalitis is an important and potentially fatal
manifestation of toxoplasmosis in immune-compromised patients including patients with
AIDS. Symptoms may include headache, disorientation, drowsiness, hemiparesis, reflex
changes, and convulsions. Coma and death also occur frequently (Hill and Dubey, 2002).
Toxoplasmic encephalitis frequently occurs in AIDS patients following reactivation of a
latent infection due to the long term presence of the tissue cyst stages of the parasite.
Acute toxoplasmasis acquired during pregnancy may result in the death of the
fetus or in serious congenital complications such as blindness, deafness or central
nervous system disorders (Switaj et al., 2005). Thus, the importance of the organism as a
pathogen of humans and domestic animals has inspired a significant amount of research
in recent years.
Biology, Life Cycle, and Transmission of T. gondii
Intracellular stages of T. gondii in the vertebrate host are found in many types of
cells and tissues, including muscle tissue, brain tissue, and intestinal epithelium. Members
of the family Felidae serve as definitive hosts for T. gondii, and a wide variety of birds and
mammals serve as intermediate hosts (McCarthy and Davis, 2003). Toxoplasmosis is
transmitted to humans generally by the ingestion of tissue cysts in infected meat or by the
ingestion of oocyst stages present in food contaminated with cat feces. Bradyzoites
released from the tissue cysts or sporozoite stages released from oocysts penetrate
intestinal epithelial cells and begin to multiply. The process of host cell invasion is
facilitated by apical organelles which are unique to organisms in the
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phylum “Apicomplexa” (Kim and Weiss, 2004). Studies of T. gondii have revealed that
host cell invasion is a carefully organized process that is accompanied by the sequential
release of micronemes, rhoptries and also by dense granules. Within the host cell, the
parasite resides within a specialized vacuole termed a “parasitophorous vacuole” that
forms from the plasma membrane during invasion, but remains segregated from other
endocytic compartments. This parasitophorous vacuole does not acidify or fuse with the
host lysosomal system (Shaw et al., 1998). Toxoplasma gondii shares many features with
other Apicomplexan parasites but is unusual in its extremely broad host and tissue
specificity. The parasite exhibits typical 'zoite' morphology, its highly polar structure
being dictated by the complex cytoskeleton. Molecules on the surface of the zoite are
prime candidates for interaction with the host cell (Smith, 1993).
The life cycle of the parasite is divided between the feline and non-feline
infections, which are correlated with the sexual and asexual phases of replication
respectively (Black and Boothroyd, 2000). The sexual stages of the parasite occur within
the intestinal enterocytes of Felids. After ingestion of the tissue cysts, liberated parasites
invade the enterocytes, undergo several rounds of division and differentiate into micro &
macro gametocytes. The gametocytes fuse to form a zygote or “oocyst” that is shed into
the environment with the cat’s feces. The oocyst undergoes meiosis, producing an octet
of highly infectious “sporozoites” that are resistant to environmental damage and may
persist for years in a moist environment (Denkers and Gazzinelli, 1998). Soil and plants
contaminated with oocysts are the most common sources of infection for herbivorous
intermediate hosts such as cattle, sheep, and rodents.
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In the intermediate host, T. gondii undergoes an asexual phase in its life cycle that
includes rapidly multiplying tachyzoites as well as slowly multiplying bradyzoites
(Dubey and Beattie, 1988). The rapid replication and dissemination of tachyzoite stages in
the intermediate host is responsible for the acute phase of the disease. Bradyzoites
(characterized by their low metabolic activity and slow rate of replication) remain in the
tissues within tissue cysts which appear 7 to 10 days post infection. These tissue cysts are
found predominantly in the central nervous system and in the muscle tissues where they
may reside for the life of the host (Black and Boothroyd, 2000). The development of the
tissue cysts throughout the body signals the chronic stage of the infection.
Tachyzoites are approximately 5µm long and replicate inside the cell with a
generation time of 6-8 hrs (Black and Boothroyd, 2000). When the host cell becomes
packed with tachyzoites, the host cell plasma membrane ruptures and the parasites are
released into the extra-cellular milieu. The free tachyzoites can then infect any nucleated
cell and continue their intracellular replication. These tachyzoite stages are highly
virulent if they are not controlled by the host immune system (Dubey et al., 1998).
Generalized toxoplasmosisis due to the uncontrolled replication of tachyzoite stages is
always fatal (Denkers and Gazzinelli, 1998). Indeed, many studies show that normally
avirulent strains of T. gondii are highly virulent in T-lymphocyte deficient animals
(Gazzinelli et al., 1991). In immuno-competent hosts, the immune response intensifies,
the reproduction of the parasite slows and numerous bradyzoites develop inside the cells
of the nervous system, heart, and muscles.
Transmission of T. gondii also occurs through blood transfusions and organ
transplants. Tissue cysts within the transplanted tissues of the donor or in the latently
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infected transplant patient are the most likely source of the infection (Hill and Dubey,
2002).
Immunity & Pathogenesis
During the acute phase of infection with T. gondii, the proliferation of tachyzoite
stages results in the death of the involved host cell and the stimulation of a mononuclear
inflammatory reaction (Plorde, 1990). The parasite may then spread to local organs and to
distant organs by the lymphatic system and bloodstream. The most common symptoms of
acute toxoplasmosis are painful, swollen lymph glands, fever, headache, muscle pain,
anemia, and possible lung complications. In immune-deficient hosts, rapid multiplication
of the tachyzoites results in necrosis in the intestinal and mesenteric lymph nodes. Focal
areas of necrosis may then develop in many other organs. In normal
immune-competent hosts, T. gondii infection is controlled by a strong cell-mediated
immune response that shuts down replication of tachyzoites and leads to the formation of
dormant tissue cysts (Roberts and Janovy, 1996). Cell mediated immunity is thought to
be the major host factor preventing the reaction of chronic infection as well as
determining the acquired resistance to re-infection ( Gazzenelli et al., 1991). Both CD4+
and CD8+ T cells responses are involved in the resolution of the infection (Khan et al.,
1994). Natural killer (NK) cells also appear to play a critical role during T. gondii
infection due to the production of interferon gamma (IFN-γ), which in turn activates
macrophages into a microbicidal state. Many studies have implicated IFN- γ as a major
cytokine involved in the immunological control of acute infection and the prevention of
reactivation of latent infection (Araujo, 1992).
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The cytokines IL-2 and IL-12 also appear to be principal mediators of
immunological resistance during T. gondii infection ( Khan et al, 1994). IL-2 is required
for priming and maintaining a Th1 controlled cell-mediated host response, and IL-12 is an
essential cytokine that stimulates the proliferation of NK cells and CD8+ T cells (Araujo,
1992). Chronic infection results when immunity builds up sufficiently to depress
tachyzoite proliferation and stimulate the formation of tissues cysts. Chronic active or
relapsing infection within retinal cells by tachyzoites can cause blind spots and extensive
infections of the central macular area, which may lead to blindness (Roberts and Janovy,
1996).
Congenital infection with T. gondii occurs through the acute infection of the
expectant mother. The severity of congenital infection depends on the stage of the
pregnancy at the time of acute infection (Black and Boothroyd, 2000). Spontaneous
abortions and congenital neurological disorders such as blindness and mental retardation
commonly occur. Congenital toxoplasmosis is also a frequent cause of intracerebral
focal lesions resulting in toxoplasmic encephalitis (Wong and Remington, 1993).

T regulatory cells
Our immune system generally protects us from an infinite number of potentially
pathogenic microorganisms while avoiding the constituents of our own body. This
phenomenon is known as “self tolerance”. Failure of immunologic self tolerance often
leads to the development of “autoimmune disease” (Sakaguchi, 2000). The thymus plays
an important role in the maintenance of self tolerance, due to its role in the clonal
deletion of self reactive T cells however, additional mechanisms including the induction
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of T cell anergy, and “immunological ignorance” are believed to be necessary for the
maintenance of peripheral self-tolerance (Zinkernagel, 1997).
The existence of lymphocyte populations that suppress adaptive immune
responses (both antibody-mediated and cell mediated) has been proposed by many
different investigators since the early 1970’s. T cells capable of suppressing the
development of autoimmune diseases –so-called “suppressor T cells” - were first
proposed by Gershon and Kondo in 1971. Suppressor T cells were thought to be a
specialized population, whose effects were mediated by secreted antigen specific factors.
It was suggested that these suppressor T cells restricted the induction or expression of
effector T cells and thereby prevented or terminated exaggerated responses or, in the case
of self-reactive T cells, autoimmune disease (Garra and Vieira, 2004). These suppressor T
cells were believed to represent a crucial element in the regulatory network responsible
for controlling immune responses and maintaining peripheral tolerance (Mittrucker et al.,
2004). Following multiple failed attempts to elucidate the molecular basis for T
suppressor cell activity, the concept of the T suppressor cell fell rapidly out of favor, and
the term disappeared from the immunological literature for many years.
In 1995, Sakaguchi and his associates described a population of naturally
occurring CD4+ CD25+ T cells in mice that constituted approximately 5-10% of all T
helper (Th) cells. These CD4+ CD25+ T cells were shown to exhibit potent regulatory
functions both in vitro and in vivo (Sakaguchi et al., 1995; Sakaguchi et al., 2001). These
“suppressor T cells”, now less provocatively renamed “regulatory” T cells (Treg cells),
have been isolated from both mice and humans, and their suppressive or regulatory
capacity has been convincingly demonstrated. Although it is clear that the clonal deletion
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of self-reactive T cells in the thymus is responsible for central tolerance, the presence of
auto-reactive T cells in normal healthy individuals indicates that potentially pathogenic,
self-reactive T cells form a part of the normal T cell repertoire (Fowell and Mason,
1993).

Development of naturally occurring CD4+CD25+ regulatory T cells
The thymus has been shown to be an important organ in the generation of Treg
cells. Papiernik et al. (1997) were the first to demonstrate the presence of CD25+ T cells
in the thymus. In their studies, the expression of CD25 appeared to be induced at the
CD4+ single positive stage in both humans and in rodents ( Beissert et al, 2006). These
Treg cells were shown to inhibit T-cell proliferation and the development of
inflammatory bowel disease as well as diabetes in mice (Sakaguchi et al., 2001).
Therefore, an important role for these cells in the prevention of autoimmunity was
demonstrated.
The results of grafting studies revealed that the thymic epithelium is involved in
the differentiation of Treg cells. Grafting of allogeneic thymic epithelium induced
tolerance to a variety of peripheral tissues of donor origin, and this tolerance was shown
to be mediated by CD4+ T cells (Maloy and Powrie, 2001). Thymic cortical epithelial
cells (positive for Class I and Class II major histocompatibility complex proteins)
appear to play a key role in the positive selection of CD4+CD25+ T cells (Bensinger et
al., 2001). Fluorochrome labeling studies showed that CD25+ cells migrate from
thymus to populate secondary lymphoid organs and tissues.
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The identification of CD25+ T cells in the CD4+CD8- peripheral T cell pool gave rise to
the hypothesis that these cells might interact with thymic medullary Dendritic Cells (DCs)
during the process of negative selection (Shevach, 2001). Thymic elements resistant to
radiation have been shown to mediate negative selection of the CD4+CD25+ cells within
the thymus. CD25 expression is acquired relatively late in thymocyte development, as
the cell progresses from the CD4+CD8+ double positive stage to the CD4+CD8- stage.
This observation prompted the suggestion that those thymocytes that develop into
CD4+CD25+ cells may express a T cell receptor( TCR) with a relatively high affinity for
self-peptides presented in the thymus (Jordan, 2001). In this scheme, Treg cell
development in the thymus would be directed by relatively high avidity interactions
between the TCR and self peptide ligands expressed on thymic Antigen Presenting Cells
(APCs). Lower avidity interactions would predominantly promote the development of
conventional CD4+CD25- thymocytes. Higher avidity interactions would lead to clonal
deletion, and the Treg cells which have lower avidity would represent only a small
proportion of positively selected thymocytes, perhaps just enough to maintain selftolerance in the periphery. Therefore, those T cells in the peripheral repertoire with the
highest intrinsic affinity for self- peptide/major histocompatibility complex (MHC)
would be the Treg cells (Ramsdel, 2003).
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In humans, Treg cells have been found in the thymus, in peripheral blood, in
lymphoid organs (tonsils and spleen), and in umbilical venous blood. The human studies
carried out so far show many similarities to murine in vitro studies, indicating that similar
mechanisms are involved in both man and mice.

Phenotypic and functional characterization of CD4+ CD25+ regulatory T cells
Naturally occurring Treg cells represent a subset of CD4+ T cells that meture in
thymus. They are characterized by the constitutive expression of CD25 and expression of
the transcription factor called Forkhead box p3 (Foxp3), which is a member of
forkhead/winged-helix family of proteins.
The expression of FOXp3 appears to be a unique and essential characteristic of
naturally occurring Treg cells (Brunkow et al., 2001). Both mice and humans deficient in
functional Foxp3 protein suffer from severe autoimmune disease symptoms (Ramsdell,
2003). In addition, analysis of the genetic defects in patients and mice suffering from
similar X-linked recessive autoimmune and inflammatory disorders, revealed mutations in
Foxp3 (Wildin, 2001). Many other transcription factors also play an important role in the
development and lineage commitment of T cells. T-bet has been shown to control the Th
type 1 (Th1) cells, and GATA-3 controls the Th type 2 (Th2) cells (Finotto and Glimcher,
2004).
A classic characteristic of CD4+ CD25+ T cells is their lack of a proliferative
response following Tcell receptor (TcR) activation or stimulation with mitogenic
antibodies. However, it is clear from murine studies that CD4+CD25+ T cells must be
activated via their TCR to exert their inhibitory function. A variety of studies have
suggested that CD4+CD25+ T cells play a role in the suppression of responses to viral,

13

bacterial, and protozoal infections (Sakaguchi, 2003). Additionally, CD4+CD25+ T cells
have been shown to suppress protective anti-tumor immunity (Wang et al., 2004). In
contrast, blocking Treg function with a neutralizing antibody directed against the
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induced an increased protective
immune response (Loser et al., 2005).
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a protein that is preferentially
expressed by Treg cells. Optimal T cell proliferation and acquisition of effector functions
requires intracellular signals elicited by both the T cell receptor and by a co -receptor,
CD28 (Carreno and Collins, 2002). Although CTLA- 4 binds to the same ligands as CD28
(with much higher affinity), its activation leads to T cell anergy (inactivation). CD28 and
CTLA-4 also differ in their expression on different subsets of T cells. CD28 is expressed
on most CD4+ T cells and almost all CD8+ T cells, whereas CTLA-4 expression is
induced in all T cells transiently after T cell receptor activation. However, among nonactivated (resting) CD4+ T cells, CTLA-4 is constitutively expressed on T cells that
express Foxp3 (Ziegler, 2006).
A number of caveats preclude the use of CD25 as a unique marker of T reg cells.
CD25 is transiently expressed upon the activation of murine Th cells, and its expression
is very dynamic (Annacker et al., 2001). The CD4+CD25+ T cell population appears to
be heterogeneous, and it is assumed that only a portion of this uncharacterized population
of cells exerts regulatory/ suppressive activity (i.e. CD4+ CD25+high cells) (Jason et al.,
2003).
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Immune regulation by Treg cells
The suppression or regulation of immune responses by T cells occurs by various
pathways. If non-professional APCs present antigens to T cells and there is an absence or
reduced expression of co-stimulatory molecules such as CD80 or CD86 (also known as
B7.1 and B7.2), the result is deficient immune activation and anergy. Anergy is also
induced if CTLA-4 is expressed by T cells at the time of antigen presentation. The
CTLA-4 glycoprotein interacts with either CD80 or CD86 on dendritic cells and results
in the production of indoleamine 2, 3-dioxygenase (IDO). The IDO metabolizes
tryptophan and leads to a decrease in the activation of T cells (Maggi et al., 2005;
Romagnani, 2006; von Boehmer, 2005).
The interaction of Fas and Fas-ligand (FasL) has been shown to induce the
apoptosis of FasL+ T cells. The binding of Fas to FasL leads to the activation of caspase
enzymes which results in the degradation of chromosomal DNA and apoptotic cell death
(Romagnani, 2006). Stimulation of CD4+CD25+Foxp3+ cells via CD3 and CD46 upregulates the expression of granzyme A, allowing Tregs to induce the apoptosis of CD4+
and CD8+T cells by perforin-granzyme mediated activation of the caspase pathway
(Romagnani, 2006).
The suppressive function of Treg cells is reported to be enhanced in the presence
of low interleukin 2 (IL-2) concentrations. This is explained by the fact that Treg cells
have a higher level of IL-2 receptor expression; thereby possessing a greater ability to
utilize the cytokine and thus deprive other T cells access to IL-2. The cytokine known as
IL-2 is a T cell growth factor that is essential for T cell proliferation. Its deficiency
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results in hampered T cell multiplication and activation. This was postulated to be an
important mechanism of Treg suppression that is independent of cytokines such as IL-10
and TGF-β (van Oosterhout and Bloksma, 2005; Yamazaki et al., 2006; Chatila, 2005).
In patients with atopic dermatitis, there is a remarkable absence of
CD4+CD25+Foxp3+ Treg cells within skin lesions, and a correlated lack of effector T
cell suppression (Verhagen et al., 2006). One of the major cytokines produced by Tregulatory cells is IL-10. This cytokine directly and indirectly suppresses the activity of
mast cells, basophils and eosinophils (Taams et al., 2006). IL-10 also prevents
immunoglobulin heavy class switching from IgG4 to IgE (Akdis, 2008; Meiler et al.,
2008). These functions are also carried out by the cytokine TGF-β, which is also
secreted by Treg cells. TGFβ interacts with fibroblasts and myofibroblasts and is known
to reduce peribronchiolar extracellular matrix deposition and airway smooth muscle cell
proliferation. Mast cell degranulation is also suppressed by the interaction of OX40 on
the surface of Tregs with OX40 ligand (OX40L) on mast cells (Gri et al., 2008).
Treg cells have also been shown to prevent the secretion of IL-9 and IL-3 by Th2
cells, thereby preventing mucus production in the lung. They also inhibit the function of
the Th1 CD4+T cells and the production of Th1 cytokines in addition to suppressing
CD8+ T cell activity (Romagnani, 2006). The suppressive effect of the Tregs on these
various immune cells consequently results in reduced allergic pathology.

Treg cells in the control of autoimmune pathology
Studies utilizing a number of different experimental models of organ-specific
autoimmune disease provide convincing evidence that specialized Treg cells capable of
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controlling autoimmunity are an integral part of the T- cell repertoire in normal
individuals. These models have common characteristics: they usually involve
manipulation of lymphocyte homeostasis, particularly influencing the thymus or
peripheral T cells, and autoimmunity can be inhibited by adoptive transfer of CD4+ T
cells from normal animals (Shevach, 2001; Sakaguchi, 2000). The CD4+CD8- population
of thymocytes is a potent source of Treg cells that adoptively transfer protection from
auto immune diabetes in rodent models (Saoudi et al., 1996). Autoimmune disease can be
induced by reconstituting immunodeficient nude mice with CD4+ T cells from normal
adult mice that have been depleted of CD4+ CD25+ T cells (Sakaguchi et al., 1995).
CD4+ CD25+ T cells prevent the development of autoimmunity induced by their
CD4+CD25- counterparts, which confirms that Treg cells are predominantly present in
the CD4+CD25+ T cell population (Asano et al., 1996).

T regulatory cells in infectious disease
It has been suggested that several types of regulatory cells may exist, including
Treg cells that are induced in response to infectious challenge (Bluestone and Abbas,
2003; Piccirillo and Shevach, 2004). Treg cells have been shown to respond to a large
variety of self antigens, and growing evidence suggests that these cells may also respond
to antigens expressed by microbes. Natural Treg cells appear to be associated most often
with chronic infections. The influence of natural Treg cells may favorably affect the
outcome of infection, or they may be harmful to the host (Belkaid and Tarbell, 2009).
However, it is important to note that the outcome of infection is also affected by a
variety of other factors. These factors include the stage of infection, dose of the
pathogen, genotype and immunological status of the host, as well as the presence of
concomitant disease or other infections (Belkaid and Rouse, 2005).
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Some of the earliest studies of natural Treg cells emphasized that such cells help
control the extent of immune-mediated pathology. In fact, a chief function of natural Treg
cells may be to respond to signals associated with tissue destruction. It has been
suggested that Treg cells may function to minimize collateral tissue damage triggered by
inflammation (Powrie et al., 2003). Treg cells have been shown to act as chief regulators
of intestinal lesion formation in mouse models of colitis. Generally, targets of natural
Treg cells could include components of the innate immune system as well as T cells
capable of causing immune pathology (Maloy, 2003).
Treg cells have also been shown to enhance pathogen survival and, in some cases,
even support the long-term persistence of the pathogen. The mouse model of L. major
infection provides a good example of this phenomenon. Natural Treg cells accumulate at
the site of infection by L. major and limit the efficacy of Th1 immune responses (by both
IL-10-dependent and IL-10-independent pathways) (Mendez et a, 2004). As a
consequence, the natural Treg cells promote pathogen persistence and potential
transmission to other hosts. Removal of natural Treg cells leads to “sterile cure”, a state
that is not compatible with the preservation of long-term immunity (Belkaid and Rouse,
2005; Belkaid and Tarbell, 2009).
A number of investigators have suggested that other pathogens may be able to
increase their survival by exploiting the Treg cell population in their host (Ge et al.,
2008. However, recent evidence suggests that monoclonal antibody depletion of Treg
cells from mice prior to and during challenge with a lethal strain of the protozoan
parasite Trypanosoma cruzi, neither improved nor worsened the outcome of infection
(Kotner and Tarleton, 2007). A similar study published in 2008 (Sales et al., 2008)
provided evidence for only slightly enhanced resistance to infection with the Colombian
strain of T. cruzi (lower parasitemia and mortality) following in vivo depletion of
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CD4+CD25+ T cells. The authors concluded that CD4+CD25+ cells play only a
limited role in host resistance during early T. cruzi infection (Sales et al., 2008).
The primary goal of the present study was to determine the impact of in vivo
depletion of CD4+CD25+ Treg cells in a murine model of infection with the protozoan
parasite, T. gondii. Specific aims of the study were as follows: 1) to successfully grow the
7D4 hybridoma cell line in culture and isolate sufficient quantities of anti-CD25
monoclonal antibodies for depletion studies, 2) to optimize an immune-fluorescent
protocol for evaluating the success of in vivo depletion of CD25+ T lymphocytes, and 3)
to evaluate the impact of CD25+ T-cell depletion on mortality, weight, and tissue cyst
burdens in mice infected with the ME49 strain of T. gondii.

MATERIALS AND METHODS
Mice
Female Swiss Webster mice were obtained from Hilltop Laboratories (Scottsdale,
PA), and C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor. ME).
C57BL/6J mice were used in one preliminary experiment, Swiss Webster mice were used
for all other experiments. C57BL/6J mice are highly susceptible to the ME49 strain of T.
gondii, and typically develop severe encephalitis during the course of infection. Swiss
Webster mice are more resistant to the ME49 strain and are commonly used as a model of
T. gondii infection with the expected resolution of the acute phase of infection and
development of tissue cysts in the chronic phase. All mice were 6 to 7 weeks of age at the
initiation of each experiment. In addition, the mice were housed in plastic box cages (5
mice per cage) in a Super Mouse 750 cage system (Lab Products, Seaford, DE) and were
provided rodent chow and water ad libitum.

Toxoplasma gondii infection
Tissue cysts of the ME49 strain of T. gondii were used to infect mice. Swiss
Webster mice in the chronic stage of infection were killed by administering an overdose
of the inhalant anesthesia, isoflurane. Cervical dislocation was then performed to ensure
death. Brains were removed and disrupted using a Pyrex homogenizer and Teflon pestle.
Tissue cysts number was determined by the method described by Huskinson-Mark et al.
(1991). Two 15-µl aliquots of each sample of brain homogenate were counted using a
hemacytometer. Each experimental mouse was infected by intraperitoneal (i.p.) injection
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with 1000 tissue cysts (preliminary experiment) or 20 tissue cysts (all other experiments)
diluted in sterile phosphate buffered saline (PBS).

In vivo depletion with anti-CD25 monoclonal antibody
A B cell hybridoma cell line (7D4; American Type Culture Collection) secreting
antibody specific for the interleukin-2 (IL-2) receptor alpha chain was grown in proteinfree hybridoma medium II (PFHM; Invitrogen Corporation, Carlsbad, CA). Culture
supernatants were routinely harvested, spun at 400xg to remove cells and debris, filtered
through a 0.22 µ m filter, and stored for less than 2 months at 4°C. To precipitate the
antibodies, an equal amount of ice-cold saturated ammonium sulfate solution was added
to the hybridoma supernatant, mixed at 4°C with a stir bar for 24h, and then spun at
1,500xg in a centrifuge for 30 min at 4°C. Protein pellets were resuspended in PBS and
then dialyzed until isotonic against PBS at a temperature of 4°C. Protein concentration
was determined by the modified Bradford assay (Bradford, 1976). The antibody solution
was then filter sterilized using a 0.22µm filter, and stored at- 80°C.
Mice were depleted of CD25 + T cells by intraperitoneal (i.p.) injection with
400µg of the anti-CD25 monoclonal antibody (Mab). Mice were injected once 7day
prior to infection, and a second time 1 day prior to infection, with 20 tissue cysts of T.
gondii. Previous investigators successfully depleted CD25+ T Cells using this Mab at
concentrations ranging from 250µg to 1000µg (Kortner and Torleton, 2007). A direct
immunofluorescence assy (IFA) was used to assess the degree of depletion of CD25+ T
cells. An FITC-conjugated anti-CD25 Mab (Rat anti-Mouse CD25/IL-2RA-FITC;
Southern Biotech, Pittsburg, PA) was used in the direct IFA performed on spleen cells
isolated from representative mice from each treatment group on the day of infection.
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Spleen cell preparation and immunofluorescence assay
Representative mice from each group were killed by administering an overdose of
the inhalant anesthesia, isoflurane. Cervical dislocation was then performed to ensure
death. Spleens were removed from each mouse and transferred to separate small Petri
dishes containing 4-5 ml of PFHM. Splenocytes were dissociated from the capsule by
repeated squeezing with long, curved forceps. The resulting cell suspension was then
passed one time through a 22 gauge needle and one time through a 26 gauge needle to
achieve a single cell suspension. The entire preparation of splenocytes was then spun at
1000 xg in a bench top centrifuge for 5 min. After decanting the supernatant, the pellet
was resuspended in 500µ l of PFHM. Erythrocytes were lysed by adding 500µ l of D.I.
water, and then isotonicity was restored in less than 10 sec by adding 500µ l of 10X PBS.
Five ml of PFHM was added to the suspension, and the tube was then spun at 1000 xg.
The supernatant was decanted, and 4-5 ml of PFHM was used to resuspend the pellet.
A direct IFA was performed on splenocytes using a rat anti-mouse CD25/IL2RA-FITC conjugated monoclonal antibody (Mab; Southern Biotech, Birmingham, AL).
One ml of each splenocyte suspension was placed into a 1.5 ml centrifuge tube and tubes
were spun by centrifugation at 4000xg for 4 to 5 min. The supernatant was discarded and
the pellet was resuspended thoroughly in 250µ l of FITC-conjugated Mab diluted 1/50 in
PFHM. Splenocytes were incubated in the Mab solution for 1 hr at RT with occasional
agitation of the tube. Cells were then washed 4 times with at least 1ml of PFHM by
repeated centrifugation at 4000 xg for 4-5 min. Cells were fixed by resuspending the
final cell pellet in 250µ l of neutral buffered formalin for 1hr on ice. Cells were washed 4
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times with 1ml of PFHM, and the final pellet was resuspended in 250µ l of PFHM and
stained cells were observed by fluorescence microscopy.

Experimental design
The role of CD25+ Treg cells in experimental toxoplasmosis was examined in one
preliminary experiment and two follow-up experiments. In the first preliminary
experiment, six C57BL/6J mice were divided randomly into two groups of three mice.
Mice in the first group were injected with the anti-CD25 Mab once, 7 day prior to the
infection , and second time one day prior to infection with 1000 tissue cysts of the ME49
strain of T .gondii. Mice in the second group were injected with PBS one week and one
day prior to infection with 1000 tissue cysts of the ME49 strain of T. gondii. Treatment
groups are shown in Table 1.

Group 1

Group2

Number of mice

3

3

Anti-CD25 (400 µg)

+

_

T. gondii infection (1000 tissue cysts)

+

+

Table 1. Experimental design of preliminary experiment.
Two additional experiments were performed using female Swiss Webster mice and the
ME49 strain of T. gondii. In the first trial, 15 female Swiss Webster mice (6-7 wks of
age) were weighed upon arrival and randomly separated into 3 cages. Mice were
numbered by ear punch, placed into cages, and provided with rodent chow (Purina rodent
chow #5001, Richmond, IN) and water ad libitum. Treatment groups are shown in Table
2.
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Group1

Group2

Group3

Number of mice

5 Mice

5mice

5mice

Anti-CD25(400 µg)

+

+

_

T. gondii infection (20 tissuecysts) +

_

+

Table 2. Experimental design for Experiment 1- Swiss Webster mice.

In the second experimental trial, 25 female Swiss Webster mice were weighed
upon arrival and randomly separated into 5 cages (5 mice per cage). Mice were
numbered by ear punch, placed into cages, and were provided with rodent chow and
water ad libitum. Treatment groups are shown in the Table 3.

Group1

Group2

Group3

Number of mice

10

5

10

Anti-CD25(400 µg)

+

+

_

T. gondii infection(20 tissuecysts) +

_

+

Table 3. Experimental design for Experiment 2- Swiss Webster mice.

Mouse Weight and Mortality
All mice were weighed upon arrival, and weekly throughout the course of each
experiment. In addition, each animal was carefully examined every one to two days to
assess morbidity and mortality.
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Experimental tissue cyst number determination
The number of tissue cysts present in the brains of mice at six weeks post
infection was determined by the technique described by Huskinson-Mark et al. (1991).
Mice were killed by administering an overdose of the inhalant anesthesia, isoflurane, and
cervical dislocation was then performed to ensure death. Brains were removed, placed in
to 1ml 1X PBS, and disrupted using a Pyrex homogenizer and Teflon pestle. The
resulting suspension was then passed 10 times through an 18-gauge needle and 10 times
through a 22-gauge needle. Two 15-µl aliquots of each sample of brain homogenate
were then counted using a hemacytometer. Alternatively, in the second experimental
trial, brains were removed and cut in half along the mid-line. One half of the brain was
placed into 4% glutaraldehyde for later histological analysis, and the other half of the
brain was used to quantify tissue cysts according to the method described above.

Statistical Evaluation
Data were analyzed using SYSTAT. The program ANOVA (Analysis of
Variance) and a two sample T test were used to test the effect of Treg cell depletion on
mice infected with T. gondii. Dependent variables in the ANOVA included weight and
number of tissue cysts. The number of tissue cysts refers to the mean number of tissue
cysts present in the brains of mice after six weeks of infection. Weight refers to the
percent weight change over the course of the experiment. Tukey’s HSD Post Hoc
method was used for multiple comparisons of means of % weight change. A Two
sample T-test was used to compare the means of the number of the tissue cysts formed
after 6 weeks of post infection.

RESULTS
Effect of Treg cell depletion on mouse weight
Experiment 1
Figure 1 shows the effect of Treg cells depletion on the average percent weight
change in Swiss Webster mice from two weeks prior to infection to 6 weeks post
infection. Mice that were Mab-treated and infected showed the greatest average per cent
weight loss following infection. The per cent weight loss observed for mice in this group
was nearly twice that observed for mice in the PBS-treated group (Group 1: -8.855%,
Group 3: -4.103%). However, this difference was not statistically significant (P˃0.05).
Mice in the control group Mab treated but non-infected showed an average percent
weight gain of 28.6% over the course of the experiment. Turkey’s post hoc test showed
significant differences in weight change between Group 1 & Group 2 and between Group
2 & 3.

Experiment 2
Figure 2 shows the effect of Treg cell depletion on the average percent weight
change in Swiss Webster mice from two weeks prior to infection to 6 weeks post infection.
Mice that were Mab-treated and infected and mice that were PBS treated and infected
showed a nearly identical average percent weight loss over the course of infection (Group
1: -23.016%, Group 3: -23.50%). However, this difference was not statistically significant
(P˃0.050. Mice in the control group (Mab-treated but non-infected) showed a 16.6%
average weight gain during the course of the experiment. Turkey’s post hoc test showed
significant differences in weight change between Group 1 & Group 2 and between Group
2 & 3.
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Figure 1. Effect of Treg cell depletion on weights of Swiss Webster mice in experiment
1. The average per cent weight loss of mice in each group (over a period of 6 weeks post infection with T. gondii) was calculated. Values are means ± SE (n=5). ANOVA program
was used to compare the % weight change for each of the three groups. The analysis
assumed that the 3 samples from normal population with equal variance (p-value= 0.441).
Tukey’s HSD Post Hoc method was used for multiple comparisons of means of %
weight change. By the results of ANOVA and multiple comparisons (using Tukey’s
method) there is no significant difference between Groups 1 and 3. However, there are
significant differences between Groups 1 and 2 and between Groups 2 and 3(pvalue<0.05).
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Figure 2. Effect of Treg cell depletion on weights of Swiss Webster mice in experiment
2. The average per cent weight loss of mice in each group (over a period of 6 weeks post
- infection with T. gondii) was calculated. Values are means ± SE (n=10). ANOVA
program was used to compare the % weight change for each of the three groups.The
analysis assumed that the 3 samples from normal population with equal variance. F-test
was used to compare the variability of the 3 populations.Tukey’s HSD Post Hoc
method was used for multiple comparisons of means of per cent weight
change.Accordig to the results of ANOVA and multiple comparisons (using
Tukey’s method) there is no significant difference between Groups 1 and 3(Pvalue=0.192). However, there are significant differences between Groups 1 and 2 and
between Groups 2 and 3 (P-value<0.05).
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Effect of Treg cell depletion on tissue cyst number
The effect of Treg cell depletion on the number of tissue cysts was determined for
all T. gondii -infected Swiss Webster mice. Table 4 & 5 shows the average number of
tissue cysts in the brains of Swiss Webster mice inoculated i.p. with 20 tissue cysts of the
ME-49 strain of T. gondii in experiment 1 and 2 respectively. Tissue cysts were counted
six weeks post-infection.
A student T test showed no statistically significant difference (P˃0.05) in
the average number of tissue cysts present in the brains of mice in Group 1 (Mabtreated and infected) and Group 3 (PBS treated and infected) in both experiment 1
and 2.
Groups

Average No. Of Cysts

Standard Deviation

1 (Mab+ Infected)

380

±147

3 (PBS+Infected)

238

±106

Table 4: Number of tissue cysts formed in Toxoplasma gondii-infected C57BL/6J
mice in experiment No 1. Mice in Group 1 were anti-CD25 Mab-treated and infected
with 1000 tissue cysts. Mice in Group 3 were PBS treated and infected with 1000
tissue cysts. Data are presented as the average number of tissue cysts present in 1000µl
(Total brain homogenate). By the results of Two-sample T test with equal population
variances, we cannot conclude a difference in means of Groups 1 and 3(p-value=
0.136, with Degrees of Freedom (DF= 8).
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GROUPS

AVERAGE NO. OF CYSTS

Standard Deviation

1 (Mab+Infected)

350

±213

3 (PBS+Infected)

540

±115

Table 5: Number of tissue cysts formed in Toxoplasma gondii-infected Swiss
Webster mice in experiment No 2. Mice in Group 1 were anti-CD25 M ab treated
and infected with 20 tissue cysts. Mice in Group 3 were PBS treated and infected with
20 tissue cysts. Data are presented as the average number of tissue cysts present in
1000µ l (1/2 brain homogenate).By the results of Two-sample T test with equal
population variances, we cannot conclude a difference in means of groups 1 and 3(pvalue= 0.064, with Degrees of Freedom (DF= 14).

Immuno-fluorescent assay assessment of Treg cell depletion

The percentage of CD25+ T lymphocytes present in the spleens of Swiss Webster
mice following Mab-treatment or PBS-treatment was determined by a direct immunofluorescence assay. Spleens from one PBS-treated mouse and one Mab-treated mouse
were removed and a single cell suspension of splenocytes was prepared as described in
Materials & Methods. Cells were stained by direct immuno-fluorescence utilizing a rat
anti-mouse CD25/IL-2RA-FITC conjugated monoclonal antibody. Figure 3 shows the
Immuno-fluorescent assay results for experiment 1.
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Figure 3. Immuno-fluorescent assay to assess Treg cell depletion in experiment #
1. Panel A- Differential interference contrast (DIC) image at 200 x magnification
splenocytes from PBS treated mice. Panel B-FITC image at 200x magnification
splenocytes from PBS treated mice. Panel C & D represents DIC, FITC images at 1000x
magnifications of PBS treated mice respectively. Panel E - Differential interference
contrast (DIC) image at 200 x magnification of splenocytes from Mab treated mice.
Panel F- FITC image at 200 x magnifications of splenocytes from Mab treated mice.
Panel G & H represents Mab treated DIC, FITC images of Mab treated mice at 1000x
magnification. Approximately 200 cells were counted, about 10/200 cells showed
fluorescence (panels A and B), where no fluorescence could be detected in any of the
200 cells in panels E and F.
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Treg cell depletion in experiment 2:
A direct immuno-flourescence assay was performed to assess the extent of Treg
cell depletion. Cells were stained by direct immuno-fluorescence utilizing a rat antimouse CD25/IL-2RA-FITC conjugated monoclonal antibody. Figure 4 shows the
Immuno-fluorescent assay results of PBS treated and Mab treated mouse in experiment 2.

Figure 4. Immuno-fluorescent assay to assess Treg cell depletion in experiment #
2. Panel A- Differential interference contrast (DIC) image at 200 x magnification of
splenocytes from PBS treated mice. Panel B- FITC image at 200x magnification of
splenocytes from PBS treated mice. Panel C & D represents DIC, FITC images at
200x magnifications of Mab treated Mice. Approximately 200 cells were counted,
about 12/200 cells showed Fluorescence in panels A and B, and 4/200 cells showed
fluorescence in panels C and D.
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Effect of Treg cell depletion on mortality rates of mice infected with T. gondii
C57BL/6J mice are highly susceptible to the ME49 strain of T. gondii, and
typically show higher mortality rates than the more resistant Swiss Webster mice. A
preliminary experiment was performed with a total of 6 C57BL/6J mice. Three mice
were treated with anti-CD25 Mab and 3 were treated with PBS one week and one day
prior to infection with 1000 tissue cysts of T. gondii. Mice in both treatment groups
showed 100% mortality prior to the end of the second week of infection.
Mortality rates of Swiss Webster mice differed between experiments 1 and 2. In
experiment 1, no mortality was observed over the six weeks of infection (data not
shown). In contrast, in experiment 2, a 40% mortality rate occurred in group 3 (PBS
treated and infected); whereas no mortality was observed in groups 1 or 2. Figure 5
shows the effect of anti-CD25 Mab-Treatment on survival of T. gondii infected mice in
experiment 2.
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Figure 5. Effect of anti-CD25 Mab-treatment on survival of Toxoplasma gondiiinfected mice in experiment 2. Swiss Webster mice were injected with 400 µg antiCD25 Mab or PBS one week and one day prior to infection with T. gondii. Percent
survival for each group (10 mice per group) is shown.

DISCUSSION

T regulatory cells play an important role in our immune system in regulating the
activity of other T lymphocytes. The Treg cells possess specialized membrane
glycoproteins known as CD4 and CD25, and express the transcription factor known as
Foxp3. These CD4+ CD25+ Foxp3+ Treg cells comprise approximately 5 to 10% of total
peripheral CD4+ T cells (Kotner and Tarleton, 2007). These cells are known to play a
key role in the regulation of the immune response to tumors and infectious agents and
also provide protection against autoimmune diseases. Many studies have provided
evidence for the suppressive effects of Treg lymphocytes against effector CD4+ Tcells
(Belkaid, 2003, Kotner and Tarleton, 2007; and Couper et al., 2009) In addition, the
results of a variety of recent studies have provided evidence that Treg cells also have the
ability to suppress cytokine production and proliferation of CD8+ T lymphocytes
(Belkaid and Tarbell, 2009). These findings have led several investigators to suggest that
the immunosuppressive function of Treg cells makes them a potential target for
manipulation by some parasites for host immune evasion (Belkaid and Rouse, 2005;
Kotner and Tarleton, 2007).
Several studies have been conducted to investigate the antigen specificity and
response of natural Treg cells during infection with Leishmania. Parasite-specific Treg
cells have been shown to accumulate at the site of infection during chronic Leishmania
infection in mice, and have been found to proliferate strongly in response to infected
dendritic cells in vitro (Suffia et al., 2006). In addition, Foxp3 mRNA expression levels
have been measured in tissues from patients with Acute Cutaneous Leishmaniasis (ACL)
and Chronic Cutaneous Leishmaniasis (CCL) (Bourreau et al., 2009).
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These investigators demonstrated that Treg cells preferentially accumulate in
lesions from ACL patients during the early phase of infection. In addition, levels of
Foxp3 mRNA transcripts were significantly higher in specimens from patients with CCL
than in those from patients with ACL suggesting a critical role of intralesional Treg cells.
These intralesional Treg cells from both the ACL and CCL patients were shown to have
suppressive functions in vitro since they inhibited IFN-γ production by CD4+CD25+ T
cells (Bourreau et al., 2009). In contrast, CD4+CD25+ cells have been shown to play
only a limited role in host resistance in murine models of infection with the protozoan
parasite, T. cruzi (Kotner and Tarleton, 2007; Sales et al., 2008).
The purpose of the present study was to evaluate the role of Treg lymphocytes in
a mouse model of infection with the protozoan parasite, Toxoplasma gondii. In this
study, the impact of CD25+ cell depletion prior to infection was investigated in both
C57BL/6 and Swiss Webster mice. C57BL/6J mice are highly susceptible to the ME49
strain of T. gondii, whereas Swiss Webster mice are more resistant and are commonly
used as a model of T. gondii-infection with the expected resolution of the acute phase of
infection. The effect of CD25+ cell depletion on the course of infection was evaluated by
monitoring weight, tissue cysts numbers, and mortality.
In a small-scale preliminary experiment, C57Bl6 mice were depleted of Treg cells
using an anti-CD25 Mab, or were sham injected with PBS. In vivo injection of anti-IL-2
receptor alpha-chain- specific Mabs has been shown to deplete Treg cells and abrogate
their suppressive effects (Belkaid and Tarbell, 2009). Mice were then infected with 1000
tissue cysts of T. gondii, and were observed daily for signs of morbidity and mortality. A
mortality rate of 100% was observed in both groups of infected mice prior to the third
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week of infection. In this highly susceptible mouse model, using relatively high numbers
of tissue cysts, the depletion of CD25+ cells prior to infection appeared to have negligible
impact on the outcome of infection. For subsequent experiments, we used Swiss Webster
mice, which are more resistant to the ME49 strain of T. gondii. We also used a lower
infectious dose of 20 tissue cysts per mouse in attempt to avoid high rates of mortality
during the acute phase of infection.
In the two experiments utilizing Swiss Webster mice, we evaluated the effect of
Treg cell depletion on mice by recording weight changes, mortality rates, and number of
tissue cysts present in mouse brains at six weeks post-infection. Over the course of the
first experiment we observed weight changes in all three groups of mice. Mice in group 1,
which were Mab-treated and infected with T. gondii, showed a greater average % weight
loss following infection than mice in group 3 (PBS-treated and infected). However, these
apparent differences were not statistically significant. As expected, mice in the control
Mab-treated group (group 2) showed an increase in weight over the course of the
experiment. This result demonstrates that the Mab treatment alone did not have a
detrimental effect in control, non-infected mice.
The effect of Treg cell depletion on tissue cyst number was also determined in
experiment 1. The number of tissue cysts present in the brains of infected mice was
determined at 6 weeks post-infection. Mice in group 1 (Mab-treated and infected)
showed a greater average number of tissue cysts as compared to mice in group 3 which
were PBS-treated and infected. However, differences in average tissue cyst number
between mice in group 1 and mice in group 2 were not statistically significant.
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In a repeat experiment utilizing Swiss Webster mice, the sample size for each
group was increased to 10. In this experiment, mice in groups 1 and 3 showed a very
similar average % weight loss over the course of the experiment. In addition, there was
no significant difference in tissue cyst number between Mab-treated and PBS-treated
mice following six weeks of infection with T. gondii.
The impact of Treg cell depletion on mortality was also monitored throughout the
course of both experiments. In experiment 1, no mortality was observed up to the
termination of the experiment at six weeks post-infection. In contrast, in experiment #2
there was a significant increase in mortality observed for mice in group 3 (PBS-treated
and T. gondii-infected). A total of 4/10 mice in group 3 (PBS-treated and infected) died
within the first 3 weeks of infection. No mortality was observed for mice in group 1
(Mab-treated and infected) or in group 2 (Mab-treated and non-infected).
Near the conclusion of the present study, and during the preparation of this paper,
Couper et al. (2009) published a very similar study designed to investigate the role of
Treg cells during murine infection with T. gondii. The investigators injected C57BL/6J
mice with anti-CD25 monoclonal antibodies (Mabs) prior to and during different phases
of infection with 10 tissue cysts of the ME49 strain of T. gondii. The investigators
reported that anti-CD25 Mab-treated C57BL/6J mice showed significantly reduced
weight loss and reduced liver pathology during early acute infection (1-2 weeks). Mice
depleted of CD25+ T cells also showed significant reduction in IFN -γ production during
the early stages of infection, suggesting that effector CD4+ T cell activity was also
impaired by the anti-CD25 Mab treatment. The CD25-depleted mice showed higher
mortality rates and elevated numbers of tissue cysts in the late acute and early chronic
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stages of infection as compared to sham-injected control mice. Based upon these results,
the authors concluded that administration of anti-CD25 Mab targets effector CD4+ T
cells in addition to natural Treg cells which constitutively express CD25. Their findings
clearly illustrate the important limitations in the use of anti-CD25 Mabs to examine the
function of Treg cells in experimental models of infectious disease.
Monoclonal antibodies specific for CD25 have also been used to investigate the
role of natural Treg cells during murine infection with the protozoan parasite,
Trypanosoma cruzi (Kotner and Tarleton, 2007; Sales et al., 2008) Kortner and Tarleton
(2007) reported that parasitemia, host survival, and T. cruzi antigen-specific immune
responses were not significantly different in CD25-depleted and non-depleted control
mice. Furthermore, Treg cells were not observed in the muscle tissues of chronically
infected mice and depletion of Treg cells during chronic infection had no therapeutic
effect. Therefore, the authors concluded that CD4+ CD25+ Treg cells are not required for
T. cruzi evasion of host immune responses. In addition, the authors concluded that Treg
cells are also not responsible for CD8+ Tcell dysfunction in sites of parasite persistence
(Kotner and Tarleton, 2007).
In the present study, we used an anti-CD25 Mab, isolated from the 7D4
hybridoma cell line in an attempt to deplete CD25+ cells in mice prior to infection. Using
this approach, we were successful in achieving >95% depletion of CD25+ spleen cells
prior to infection in experiment 1. However, using the same protocol in experiment #2,
we were successful in reducing the percentage of CD25+ cells by only 33%. Depletion
results achieved by other investigators using the same or similar Mabs are typically >90%
(Kotner and Tarleton, 2007; Couper et al., 2009). The failure to achieve high levels of
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CD25+ T cell depletion in our second experimental trial, most likely led to the
differences we observed in trends in average tissue cyst burden, weight loss, and
mortality between the two experiments. It has been reported that the CD4+ CD25+ T cell
population regenerates quickly, and it may be possible to achieve more reliable levels of
depletion using additional injections of the Mab, and/or using a higher concentration of
Mab for each injection. A second important consideration is that the anti-CD25 Mab
depletes not only CD4+CD25+ Treg cells, but also activated effector T cells and other
cells that express CD25 (Couper et al, 2009). In future studies, the use of Foxp3 gene
knockout mice or Foxp3 gene silencing techniques may be a better experimental
approach for investigating the role of natural Treg cells during infection with T. gondii or
other pathogens.
Finally, the results of the present study suggest that depletion of CD25+ cells has
little measurable impact during the acute stage of infection with the ME49 strain of T.
gondii. Even in experiment 1, when nearly 100% depletion of splenic CD25+ T cells was
achieved, we observed no statistically significant differences in tissue cyst number,
weight loss, or mortality between CD25 depleted and non-depleted mice infected with T.
gondii. However, further studies will be required to fully investigate the role of Treg cells
during the acute phase of infection with T. gondii, and to determine what role, if any,
these cells might play during the chronic stage of murine toxoplasmosis.
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